Stenotrophomonas maltophilia: An emerging global opportunistic pathogen

Clinical Microbiology Reviews

Volumn 25, Issue 1, 2012, Pages 2-41

  Brooke, Joanna S ^a  

^a DEPAUL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANATE POTASSIUM PLUS TICARCILLIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; GREEN TEA EXTRACT; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; POLYMYXIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VEGETABLE OIL;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIOFILM; CELL INVASION; CLIMATE CHANGE; CONFOCAL LASER MICROSCOPY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENVIRONMENTAL FACTOR; EVOLUTIONARY ADAPTATION; GENE SEQUENCE; GENE TRANSFER; GENETIC VARIABILITY; HOSPITAL INFECTION; HOST CELL; HUMAN; INFECTION RISK; MONOTHERAPY; NANOEMULSION; NONHUMAN; PATHOGENESIS; REVIEW; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA INFECTION; TRANSMISSION ELECTRON MICROSCOPY;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; OPPORTUNISTIC INFECTIONS; PANDEMICS; STENOTROPHOMONAS MALTOPHILIA; WORLD HEALTH;

ANIMALIA; BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 84855650410     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00019-11     Document Type: Review

References (383)

1. Aaron SD, et al. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366:463-471.
2. Adjidé CC, et al. 2010. Stenotrophomonas maltophilia and Pseudomonas aeruginosa water associated microbiologic risk assessment in Amiens' University Centre. Pathol. Biol. (Paris) 58:e1-e15. doi:10.1016/ j.patbio.2009.07.006.
3. Adjidé CC, et al. 2010. A sensitive, specific and predictive isolation medium developed for Stenotrophomonas maltophilia study in healthcare settings. Pathol. Biol. (Paris) 58:11-17.
4. Akçakaya AA, et al. 2011. A cluster of acute-onset postoperative endophthalmitis over a 1-month period: investigation of an outbreak caused by uncommon species. Br. J. Ophthalmol. 95:481-484.
5. Akova M, Bonfiglio G, Livermore DM. 1991. Susceptibility to β-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high-and low-level constitutive expression of L1 and L2 β-lactamases. J. Med. Microbiol. 35:208-213.
6. Al-Hamad A, Upton M, Burnie J. 2009. Molecular cloning and characterization of SmrA, a novel ABC multidrug efflux pump from Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 64:731-734.
7. Al-Jasser AM. 2006. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann. Clin. Microbiol. Antimicrob. 5:23-25. doi:10.1186/1476-0711-5-23.
8. Al Johani SM, et al. 2010. Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia. Ann. Saudi Med. 30:364-369.
9. Al Naiemi N, Duim B, Bart A. 2006. A CTX-M extended-spectrum β-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J. Med. Microbiol. 55:1607-1608.
10. Alonso A, Martínez JL. 1997. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41: 1140-1142.
11. Alonso A, Martínez JL. 2000. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 44:3079-3086.
12. Alonso A, Sanchez P, Martínez JL. 2000. Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance. Antimicrob. Agents Chemother. 44:1778-1782.
13. Apisarnthanarak A, et al. 2003. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect. Control Hosp. Epidemiol. 24:269-274.
14. Araoka H, Baba M, Yoneyama A. 2010. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur. J. Clin. Microbiol. Infect. Dis. 29:605-608.
15. Arvanitidou M, Vayona A, Spanakis N, Tsakris A. 2003. Occurrence and antimicrobial resistance of Gram-negative bacteria isolated in haemodialysis water and dialysate of renal units: results of a Greek multicentre study. J. Appl. Microbiol. 95:180-185.
16. Avison MB, et al. 2002. Differential regulation of L1 and L2 β-lactamase expression in Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 49:387-389.
17. Avison MB, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR. 2001. Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 45:413-419.
18. Avison MB, von Heldreich CJ, Higgins CS, Bennett PM, Walsh TR. 2000.ATEM-2β-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 46:879-884.
19. Aydin K, Koksal I, Kaygusuz S, Kaklikkaya I, Caylan R, Õzdemir R. 2000. Endocarditis caused by Stenotrophomonas maltophilia. Scand. J. Infect. Dis. 32:427-430.
20. Ba BB, Feghali H, Arpin C, Saux M-C, Quentin C. 2004. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokineticpharmacodynamic model. Antimicrob. Agents Chemother. 48:946-953.
21. Babálová M, Blahová J, Lešická-Hupková M, Krcméry V, Kubonová K. 1995. Transfer of ceftazidime and aztreonam resistance from nosocomial strains of Xanthomonas (Stenotrophomonas) maltophilia to a recipient strain of Pseudomonas aeruginosa ML-1008. Eur. J. Clin. Microbiol. Infect. Dis. 14:925-927.
22. Bajaj N, Sheth AN, Burgess JJ, Husain H, Brooke JS. 2009. Disinfectant reduction of biofilm formation of Stenotrophomonas maltophilia, abstr AE4. Abstr. 59th Annu. Conf. Can. Soc. Microbiol. Canadian Society of Microbiologists, Ottawa, Ontario, Canada.
23. Ballmann M, von der Hardt H. 2002. Hypertonic saline and recombinant human DNase: a randomized crossover pilot study in patients with cystic fibrosis. J. Cyst. Fibros. 1:35-37.
24. Banerjee R, Roy D. 2009. Codon usage and gene expression pattern of Stenotrophomonas maltophilia R551-3 for pathogenic mode of living. Biochem. Biophys. Res. Commun. 390:177-181.
25. Barbeau J, ten Bokum L, Gauthier C, Prévost AP. 1998. Crosscontamination potential of salvia ejectors used in dentistry. J. Hosp. Infect. 40:303-311.
26. Barbier-Frebourg N, Boutiba-Boubaker I, Nouvellon M, Lemeland J-F. 2000. Molecular investigation of Stenotrophomonas maltophilia isolates exhibiting rapid emergence of ticarcillin-clavulanate resistance. J. Hosp. Infect. 45:35-41.
27. Barbolla R, et al. 2004. Class 1 integrons increase trimethoprimsulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob. Agents Chemother. 48: 666-669.
28. Bathe S, Lebuhn M, Ellwart JW, Wuertz S, Hausner M. 2004. High phylogenetic diversity of transconjugants carrying plasmid pJP4 in an activated sludge-derived microbial community. FEMS Microbiol. Lett. 235:215-219.
29. Berg G. 2009. Plant-microbe interactions promoting plant growth and health: perspectives for controlled use of microorganisms in agriculture. Appl. Microbiol. Biotechnol. 84:11-18.
30. Berg G, Eberl L, Hartmann A. 2005. The rhizosphere as a reservoir for opportunistic human pathogenic bacteria. Environ. Microbiol. 7:1673-1685.
31. Berg G, Roskot N, Smalla K. 1999. Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia. J. Clin. Microbiol. 37:3594-3600.
32. Berney M, Hammes F, Bosshard F, Weilenmann H-U, Egli T. 2007. Assessment and interpretation of bacterial viability by using the LIVE/ DEAD BacLight kit in combination with flow cytometry. Appl. Environ. Microbiol. 73:3283-3290.
33. Bin Abdulhak AA, Zimmerman V, Al Beirouti BT, Baddour LM, Tleyjeh IM. 2009. Stenotrophomonas maltophilia infectious of intact skin: a systematic review of the literature. Diagn. Microbiol. Infect. Dis. 63:330-333.
34. Blahová J, Králiková K, Krcméry V, Sr, Chmelarová E, Toršová V. 1998. Two nosocomial strains of Stenotrophomonas maltophilia transferring antibiotic resistance to Proteus mirabilis P-38 recipient strain. J. Chemother. 10:22-24.
35. Blondel-Hill E, Henry DA, Speert DP. 2007. Pseudomonas, p 734-748. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), Manual of clinical microbiology, 9th ed, vol 1. ASM Press, Washington, DC.
36. Bonfield TL, et al. 1995. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 152:2111-2118.
37. Borovilos M, Shulman ST, Brooke JS. 2005. Role of flagella in biofilm formation by Stenotrophomonas maltophilia, abstr B2. Abstr. 55th Annu. Conf. Can. Soc. Microbiol. Canadian Society of Microbiologists, Ottawa, Ontario, Canada.
38. Brooke JS. 2007. Biofilm production of clinical isolates of Stenotrophomonas maltophilia altered by sodium phosphate buffer supplementation of the medium. Ann. Microbiol. 57:677-679.
39. Brooke JS. 2008. Pathogenic bacteria in sink exit drains. J. Hosp. Infect. 70:198-199.
40. Brooke JS, Annand JW, Hammer A, Dembkowski K, Shulman ST. 2009. Investigation of bacterial pathogens on seventy frequently used environmental surfaces in a large urban U.S. university. J. Environ. Health 71:17-22.
41. Brooke JS, Vo A, Watts P, Davis NA. 2008. Mutation of a lipopolysaccharide synthesis gene results in increased biofilm of Stenotrophomonas maltophilia on plastic and glass surfaces. Ann. Microbiol. 58:35-40.
42. Burdge DR, Noble MA, Campbell ME, Krell VL, Speert DP. 1995. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin. Infect. Dis. 20:445-448.
43. Burns JL, et al. 1999. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179:1190-1196.
44. Calza L, Manfredi R, Chiodo F. 2003. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection 31:155-161.
45. Cantón R, et al. 2003. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates. Pediatr. Pulmonol. 35:99-107.
46. Carattoli A. 2003. Plasmid-mediated antimicrobial resistance in Salmonella enterica. Curr. Issues Mol. Biol. 5:113-122.
47. Carmeli Y, Samore MH. 1997. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin. Infect. Dis. 24:1131-1134.
48. Carmody LA, Spilker T, LiPuma JJ. 2011. Reassessment of Stenotrophomonas maltophilia phenotype. J. Clin. Microbiol. 49:1101-1103.
49. Cattoir V, Poirel L, Aubert C, Soussy C-J, Nordmann P. 2008. Unexpected occurrence of plasmid-mediated quinolone resistance determinants in environmental Aeromonas spp. Emerg. Infect. Dis. 14:231-237.
50. Caylan R, et al. 2004. An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital. Jpn. J. Infect. Dis. 57:37-40.
51. Cérémonie H, Buret F, Simonet P, Vogel TM. 2004. Isolation of lightning-competent soil bacteria. Appl. Environ. Microbiol. 70: 6342-6346.
52. Cervia JS, et al. 2010. Point-of-use water filtration reduces healthcareassociated infections in bone marrow transplant recipients. Transpl. Infect. Dis. 12:238-241.
53. Chang H-C, et al. 2005. Isolation and characterization of novel giant Stenotrophomonas maltophilia phagef{cyrillic}SMA5. Appl. Environ. Microbiol. 71:1387-1393.
54. Chang L-L, Chen H-F, Chang C-Y, Lee T-M, Wu W-J. 2004. Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 53:518-521.
55. Chang L-L, Lin H-H, Chang C-Y, Lu P-L. 2007. Increased incidence of class 1 integrons in trimethoprim/sulfamethoxazole-resistant clinical isolates of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 59: 1038-1039.
56. Chang Y-C, Huang Y-W, Chiang K-H, Yang T-C, Chung T-C. 2010. Introduction of an AmpR-L2 intergenic segment attenuates the induced β-lactamase activity of Stenotrophomonas maltophilia. Eur. J. Clin. Microbiol. Infect. Dis. 29:887-890.
57. Chatelut M, Dournes JL, Chabanon G, Marty N. 1995. Epidemiological typing of Stenotrophomonas (Xanthomonas) maltophilia by PCR. J. Clin. Microbiol. 33:912-914.
58. Chaw KC, Manimaran M, Tay FEH. 2005. Role of silver ions in destabilization of intermolecular adhesion forces measured by atomic force microscopy in Staphylococcus epidermidis biofilms. Antimicrob. Agents Chemother. 49:4853-4859.
59. Chen KJ, et al. 2010. Endophthalmitis caused by Stenotrophomonas maltophilia. Ophthalmic Surg. Lasers Imaging 41:e555-e561. doi: 10.3928/15428877-20100910-03.
60. Cicalini S, Palmieri F, Petrosillo N. 2004. Clinical review: new technologies for prevention of intravascular catheter-related infections. Crit. Care 8:157-162.
61. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A8. CLSI, Wayne, PA.
62. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. M100-S21. CLSI, Wayne, PA.
63. Coenye T, Vanlaere E, LiPuma JJ, Vandamme P. 2004. Identification of genomic groups in the genus Stenotrophomonas using gyrB RFLP analysis. FEMS Immunol. Med. Microbiol. 40:181-185.
64. Collis CM, Kim M-J, Stokes HW, Hall RM. 1998. Binding of the purified integron DNA integrase Intl1 to integron-and cassetteassociated recombination sites. Mol. Microbiol. 29:477-490.
65. Conover MS, Mishra M, Deora R. 2011. Extracellular DNA is essential for maintaining Bordetella biofilm integrity on abiotic surfaces and in the upper respiratory tract of mice. PLoS One 6:e16861. doi:10.1371/ journal.pone.0016861.
66. Critchley MM, Cromar NJ, McClure NC, Fallowfield HJ. 2003. The influence of the chemical composition of drinking water on cuprosolvency by biofilm bacteria. J. Appl. Microbiol. 94:501-507.
67. Crossman LC, et al. 2008. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol. 9:R74. doi:10.1186/gb-2008-9-4-r74.
68. Cullmann W. 1991. Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates. Chemotherapy 37: 246-250.
69. Cystic Fibrosis Foundation. 2004. Patient registry 2003. Annual data report to the center directors. Cystic Fibrosis Foundation, Bethesda, MD.
70. Dantam J, Zhu H, Stapleton F. 2011. Biocidal efficacy of silverimpregnated contact lens storage cases in vitro. Invest. Ophthalmol. Vis. Sci. 52:51-57.
71. da Silva Filho LVF, et al. 2004. Identification of Pseudomonas aeruginosa, Burkholderia cepacia complex, and Stenotrophomonas maltophilia in respiratory samples from cystic fibrosis patients using multiplex PCR. Pediatr. Pulmonol. 37:537-547.
72. Davies DG, Marques CNH. 2009. A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. J. Bacteriol. 191: 1393-1403.
73. de Abreu Vidipó L, de Andrade Marques E, Puchelle E, Plotkowski M-C. 2001. Stenotrophomonas maltophilia interaction with human epithelial respiratory cells in vitro. Microbiol. Immunol. 45:563-569.
74. De Carolis E, et al. 2011. Analysis of heat-induced changes in protein expression of Stenotrophomonas maltophilia K279a reveals a role for GroEL in the host-temperature adaptation. Int. J. Med. Microbiol. 301: 273-281.
75. De la Rosa-García SC, Muñoz-García AA, Barahona-Pérez LF, Gamboa-Angulo MM. 2007. Antimicrobial properties of moderately halotolerant bacteria from cenotes of the Yucatan peninsula. Lett. Appl. Microbiol. 45:289-294.
76. Demko CA, Stern RC, Doershuk CF. 1998. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr. Pulmonol. 25:304-308.
77. Denton M, Hall MJ, Todd NJ, Kerr KG, Littlewood JM. 2000. Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium. Clin. Microbiol. Infect. 6:385-398.
78. Denton M, Keer V, Hawkey PM. 1999. Correlation between genotype and β-lactamases of clinical and environmental strains of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 43:555-558.
79. Denton M, Kerr KG. 1998. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev. 11:57-80.
80. Denton M, et al. 2003. Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. J. Hosp. Infect. 55:180-183.
81. Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. 1998. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J. Clin. Microbiol. 36:1953-1958.
82. Denton M, Todd NJ, Littlewood JM. 1996. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 15:402-405.
83. de Oliveira-Garcia D, et al. 2003. Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces. Cell. Microbiol. 5:625-636.
84. de Oliveira-Garcia D, et al. 2002. Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia. Emerg. Infect. Dis. 8:918-923. http://www.cdc.gov/NCIDOD/eid/vol8no9/01-0535.htm.
85. Department of Health. 1993. Ice cubes: infection caused by Xanthomonas maltophilia. Hazard (93)42. Medical Services Directorate, Department of Health, London, United Kingdom.
86. Deschaght P, et al. 2011. Rapid genotyping of Achromobacter xylosoxidans, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolates using melting curve analysis of RAPD-generated DNA fragments (McRAPD). Res. Microbiol. 162:386-392.
87. Di Bonaventura G, et al. 2010. Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis. Infect. Immun. 78:2466-2476.
88. Di Bonaventura G, et al. 2007. Molecular characterization of virulence determinants of Stenotrophomonas maltophilia strains isolated from patients affected by cystic fibrosis. Int. J. Immunopathol. Pharmacol. 20: 529-537.
89. Di Bonaventura G, Spedicato I, D'Antonio D, Robuffo I, Piccolomini R. 2004. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob. Agents Chemother. 48:151-160.
90. Di Bonaventura G, Stepanović S, Picciani C, Pompilio A, Piccolomini R. 2007. Effect of environmental factors on biofilm formation by clinical Stenotrophomonas maltophilia isolates. Folia Microbiol. 52:86-90.
91. Ding X, Wu X, Peng Y, Hu S, Nie H. 2006. Risk factors of superinfection following imipenem/cilastatin therapy in hospitalised patients with acute exacerbations of severe chronic obstructive pulmonary disease. Int. J. Clin. Pract. 60:806-811.
92. Donaldson SH, et al. 2006. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 354:241-250.
93. Donlan RM. 2009. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 17:66-72.
94. Downhour NP, Petersen EA, Krueger TS, Tangella KV, Nix DE. 2002. Severe cellulitis/myositis caused by Stenotrophomonas maltophilia. Ann. Pharmacother. 36:63-66.
95. Eguchi M, et al. 1996. Responses to stress and nutrient availability by the marine ultramicrobacterium Sphingomonas sp. strain RB2256. Appl. Environ. Microbiol. 62:1287-1294.
96. Elkins MR, et al. 2006. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 354:229-240.
97. Elting LS, Bodey GP. 1990. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheterrelated infections. Medicine 69:296-306.
98. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL. 2010. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr. Pulmonol. 45:363-370.
99. Eng PA, et al. 1996. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr. Pulmonol. 21:77-83.
100. Entenza JM, Moreillon P. 2009. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34:8.e1-8.e9.
101. Ewig S, et al. 2000. Evaluation of antimicrobial treatment in mechanically ventilated patients with severe chronic obstructive pulmonary disease exacerbations. Crit. Care Med. 28:692-697.
102. Exner M, et al. 2005. Prevention and control of health care-associated waterborne infections in health care facilities. Am. J. Infect. Control 33: S26-S40.
103. Fabio A, Cermelli C, Fabio G, Nicoletti P, Quaglio P. 2007. Screening of the antibacterial effects of a variety of essential oils on microorganisms responsible for respiratory infections. Phytother. Res. 21:374-377.
104. Falagas ME, Karageorgopoulos DE. 2008. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin. Infect. Dis. 46:1121-1122.
105. Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. 2009. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 28:719-730.
106. Falagas ME, et al. 2009. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol. 4:1103-1109.
107. Falagas ME, Valkimadi P-E, Huang Y-T, Matthaiou DK, Hsueh P-R. 2008. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J. Antimicrob. Chemother. 62:889-894.
108. Farrell DJ, Sader HS, Jones RN. 2010. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob. Agents Chemother. 54:2735-2737.
109. Feazel LM, et al. 2009. Opportunistic pathogens enriched in showerhead biofilms. Proc. Natl. Acad. Sci. U. S. A. 106:16393-16399.
110. Fedler KA, Biedenbach DJ, Jones RN. 2006. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn. Microbiol. Infect. Dis. 56:427-436.
111. Figueirêdo PMS, et al. 2006. Cytotoxic activity of clinical Stenotrophomonas maltophilia. Lett. Appl. Microbiol. 43:443-449.
112. Fink MP, et al. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
113. Fouhy Y, et al. 2007. Diffusible signal factor-dependent cell-cell signaling and virulence in the nosocomial pathogen Stenotrophomonas maltophilia. J. Bacteriol. 189:4964-4968.
114. Fuchs HJ, et al. 1994. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 331:637-642.
115. Fujita J, et al. 1996. Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respir. Med. 90:35-38.
116. Furuhata K, Ishizaki N, Kawakami Y, Fukuyama M. 2010. Bacterial contamination of stock solutions in storage cases for contact lens, and the disinfectant-resistance of isolates. Biocontrol Sci. 15:81-85.
117. Furushita M, Okamoto A, Maeda T, Ohta M, Shiba T. 2005. Isolation of multidrug-resistant Stenotrophomonas maltophilia from cultured yellowtail (Seriola quinqueradiata) from a marine fish farm. Appl. Environ. Microbiol. 71:5598-5600.
118. Gabriel MM, Mayo MS, May LL, Simmons RB, Ahearn DG. 1996. In vitro evaluation of the efficacy of a silver-coated catheter. Curr. Microbiol. 33:1-5.
119. Gales AC, et al. 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis. 32:S104-S113.
120. Garcia Paez JI, Costa SF. 2008. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J. Hosp. Infect. 70:101-108.
121. Geller DE, et al. 2011. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 55:2636-2640. doi:10.1128/AAC.01744-10.
122. Gentry H, Cope S. 2005. Using silver to reduce catheter-associated urinary tract infections. Nurs. Stand. 19:51-54.
123. Gerner-Smidt P, Bruun B, Arpi M, Schmidt J. 1995. Diversity of nosocomial Xanthomonas maltophilia (Stenotrophomonas maltophilia) as determined by ribotyping. Eur. J. Clin. Microbiol. Infect. Dis. 14: 137-140.
124. Glick R, et al. 2010. Increase in rhamnolipid synthesis under ironlimiting conditions influences surface motility and biofilm formation in Pseudomonas aeruginosa. J. Bacteriol. 192:2973-2980.
125. Gordon NC, Wareham DW. 2010. Antimicrobial activity of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) against clinical isolates of Stenotrophomonas maltophilia. Int. J. Antimicrob. Agents 36: 129-131.
126. Gordon NC, Wareham DW. 2010. Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 65:483-489.
127. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. 2004. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 59:955-959.
128. Goss CH, Otto K, Aitken ML, Rubenfeld GD. 2002. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 166:356-361.
129. Gould VC, Okazaki A, Howe RA, Avison MB. 2004. Analysis of sequence variation among smeDEF multi drug efflux pump genes and flanking DNA from defined 16S rRNA subgroups of clinical Stenotrophomonas maltophilia isolates. J. Antimicrob. Chemother. 54:348-353.
130. Gradisar H, Pristovsek P, Plaper A, Jerala R. 2007. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J. Med. Chem. 50:264-271.
131. Graff GR, Burns JL. 2002. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 121:1754-1760.
132. Grare M, et al. 2010. Cationic compounds with activity against multidrug-resistant bacteria: interest of a new compound compared with two older antiseptics, hexamidine and chlorhexidine. Clin. Microbiol. Infect. 16:432-438.
133. Gülmez D, Çakar A, Sener B, Karakaya J, Hasçelik G. 2010. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J. Infect. Chemother. 16:322-328.
134. Gülmez D, Hasçelik G. 2005. Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital. Clin. Microbiol. Infect. 11:880-886.
135. Gutiérrez Rodero F, et al. 1996. Endocarditis caused by Stenotrophomonas maltophilia: case report and review. Clin. Infect. Dis. 23:1261-1265.
136. Hadjiliadis D, et al. 2007. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J. Heart Lung Transplant. 26:834-838.
137. Hall RM, Collis CM. 1995. Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. Mol. Microbiol. 15: 593-600.
138. Harris NB, Rogers DG. 2001. Septicemia associated with Stenotrophomonas maltophilia in a West African dwarf crocodile (Osteolaemus tetraspis subsp. tetraspis). J. Vet. Diagn. Invest. 13:255-258.
139. Havasi V, et al. 2008. Inhibitory effects of hypertonic saline on P. aeruginosa motility. J. Cyst. Fibros. 7:267-269.
140. Hejnar P, Bardoň J, Sauer P, Kolář M. 2007. Stenotrophomonas maltophilia as a part of normal oral bacterial flora in captive snakes and its susceptibility to antibiotics. Vet. Microbiol. 121:357-362.
141. Hejnar P, Kolář M, Sauer P. 2010. Antibiotic resistance of Stenotrophomonas maltophilia strains isolated from captive snakes. Folia Microbiol. 55:83-87.
142. Hoefel D, Monis PT, Grooby WL, Andrews S, Saint CP. 2005. Profiling bacterial survival through a water treatment process and subsequent distribution system. J. Appl. Microbiol. 99:175-186.
143. Holmes A, et al. 2009. Comparison of two multimetal resistant bacterial strains: Enterobacter sp. YSU and Stenotrophomonas maltophilia ORO2. Curr. Microbiol. 59:526-531.
144. Holmes C, Cervia JS, Ortolano GA, Canonica FP. 2010. Preventive efficacy and cost-effectiveness of point-of-use water filtration in a subacute care unit. Am. J. Infect. Control 38:69-71.
145. Holmquist L, Kjelleberg S. 1993. Changes in viability, respiratory activity and morphology of the marine Vibrio sp. strain S14 during starvation of individual nutrients and susbsequent recovery. FEMS Microbiol. Ecol. 12:215-223.
146. Hu L-F, et al. 2011. Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int. J. Antimicrob. Agents 37:230-234.
147. Hu R-M, Chiang K-H, Chang Y-C, Yang T-C. 2009. Characterization of the charge variants of L2β-lactamase in Stenotrophomonas maltophilia. J. Med. Microbiol. 58:318-321.
148. Hu R-M, Huang K-J, Wu L-T, Hsiao Y-J, Yang T-C. 2008. Induction of L1 and L2β-lactamases of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 52:1198-1200.
149. Huang T-P, Wong ACL. 2007. A cyclic AMP receptor protein-regulated cell-cell communication system mediates expression of a FecA homologue in Stenotrophomonas maltophilia. Appl. Environ. Microbiol. 73: 5034-5040.
150. Huang T-P, Wong ACL. 2007. Extracellular fatty acids facilitate flagella-independent translocation by Stenotrophomonas maltophilia. Res. Microbiol. 158:702-711.
151. Huang T-P, Somers EB, Wong ACL. 2006. Differential biofilm formation and motility associated with lipopolysaccharide/exopolysaccharidecoupled biosynthetic genes in Stenotrophomonas maltophilia. J. Bacteriol. 188:3116-3120.
152. Huang X, et al. 2009. The investigation of nematocidal activity in Stenotrophomonas maltophilia G2 and characterization of a novel virulence serine protease. Can. J. Microbiol. 55:934-942.
153. Huang Y-W, et al. 2010. An AmpN-AmpG operon is essential for expression of L1 and L2 β-lactamases in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 54:2583-2589.
154. Hugh R, Leifson E. 1963. A description of the type strain of Pseudomonas maltophilia. Int. Bull. Bacteriol. Nomencl. Taxon. 13:133-138.
155. Hupková M, Blahová J, Králiková J, Krčmery V. 1995. Transferable resistance to β-lactams in a nosocomial strain of Xanthomonas maltophilia. Antimicrob. Agents Chemother. 39:1011-1012.
156. Husain H, Burgess JJ, Sheth AN, Bajaj NH, Brooke JS. 2009. Efficacy of selected germicides on the biofilm formation of Stenotrophomonas maltophilia, abstr AE22. Abstr. 59th Annu. Conf. Can. Soc. Microbiol. Canadian Society of Microbiologists, Ottawa, Ontario, Canada.
157. Hutchinson GR, et al. 1996. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, Gramnegative bacteria in patients with cystic fibrosis. J. Clin. Microbiol. 34: 584-587.
158. Ivanov V, Stabnikov V, Zhuang WQ, Tay JH, Tay STL. 2005. Phosphate removal from the returned liquor of municipal wastewater treatment plant using iron-reducing bacteria. J. Appl. Microbiol. 98: 1152-1161.
159. Jägevall S, Rabe L, Pedersen K. 2011. Abundance and diversity of biofilms in natural and artificial aquifers of theAspö Hard Rock Laboratory, Sweden. Microb. Ecol. 61:410-422.
160. Jakobi M, et al. 1996. Maltophilin: a new antifungal compound produced by Stenotrophomonas maltophilia R3089. J. Antibiot. 49: 1101-1104.
161. Jamrozy-Witkowska AM, Grzybowski A, Grabska-Liberek I, Pawlik-Sobecka LA, Krzyzanowska-Berkowska PP. 2010. Co-existence of Staphylococcus spp and Stenotrophomonas maltophilia infection in persistent endophthalmitis after cataract surgery. Clin. Exp. Optom. 93:473-475.
162. Jang TN, Wang FD, Wang LS, Liu CY, Liu IM. 1992. Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J. Formos. Med. Assoc. 91:1170-1176.
163. Johnson EH, Al-Busaidy R, Hameed MS. 2003. An outbreak of lymphadenitis associated with Stenotrophomonas (Xanthomonas) maltophilia in Omani goats. J. Vet. Med. 50:102-104.
164. Jones CR, Chamberlain AHL, Adams MR. 1999. An investigation of the presence of ultramicrocells in natural mineral water. Lett. Appl. Microbiol. 28:275-279.
165. Jones RN. 2010. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin. Infect. Dis. 51:S81-S87.
166. Jucker BA, Harms H, Zehnder AJB. 1996. Adhesion of the positively charged bacterium Stenotrophomonas (Xanthomonas) maltophilia 70401 to glass and Teflon. J. Bacteriol. 178:5472-5479.
167. Kagen J, Zaoutis TE, McGowan KL, Luan X, Shah SS. 2007. Bloodstream infection caused by Stenotrophomonas maltophilia in children. Pediatr. Infect. Dis. J. 26:508-512.
168. Karpati F, Malmborg AS, Alfredsson H, Hjelte L, Strandvik B. 1994. Bacterial colonization with Xanthomonas maltophilia-a retrospective study in a cystic fibrosis patient population. Infection 22:258-263.
169. Kataoka D, et al. 2003. The indirect pathogenicity of Stenotrophomonas maltophilia. Int. J. Antimicrob. Agents 22:601-606.
170. Kataoka D, Fujiwara H, Tanimoto A, Ikawa S, Tanaka Y. 2003. The differential β-lactamase activity of Stenotrophomonas maltophilia. J. Hosp. Infect. 54:247-248.
171. Katayama T, Tsuruya Y, Ishikawa S. 2010. Stenotrophomonas maltophilia endocarditis of prosthetic mitral valve. Intern. Med. 49: 1775-1777.
172. Keinänen MM, et al. 2002. The microbial community structure of drinking water biofilms can be affected by phosphorus availability. Appl. Environ. Microbiol. 68:434-439.
173. Khardori N, Elting L, Wong E, Schable B, Bodey GP. 1990. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev. Infect. Dis. 12:997-1003.
174. King BA, Shannon KP, Phillips I. 1978. Aminoglycoside 6=-N acetyltransferase production by an isolate of Pseudomonas maltophilia. J. Antimicrob. Chemother. 4:467-468.
175. King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN. 2010. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob. Agents Chemother. 54:143-148.
176. Klausner JD, Zukerman C, Limaye AP, Corey L. 1999. Outbreak of Stenotrophomonas maltophilia bacteremia among patients undergoing bone marrow transplantation: association with faulty replacement of handwashing soap. Infect. Control Hosp. Epidemiol. 20:756-758.
177. Kolodkin-Gal I, et al. 2010. D-Amino acids trigger biofilm disassembly. Science 328:627-629.
178. Korakianitis I, Mirtsou V, Gougoudi E, Raftogiannis M, Giamarellos-Bourboulis EJ. 2010. Post-antibiotic effect (PAE) of moxifloxacin in multidrug-resistant Stenotrophomonas maltophilia. 36:387-389.
179. Kovaleva J, Degener JE, van der Mei HC. 2010. Mimicking disinfection and drying of biofilms in contaminated endoscopes. J. Hosp. Infect. 76: 345-350.
180. Kramer A, Schwebke I, Kampf G. 2006. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect. Dis. 6:130. doi:10.1186/1471-2334-6-130.
181. Kraus D, Peschel A. 2006. Molecular mechanisms of bacterial resistance to antimicrobial peptides. Curr. Top. Microbiol. Immunol. 306: 231-250.
182. Krcmery V, Jr, Koprnova J, Harniciarova A. 2004. Stenotrophomonas maltophilia bacteremia. Scand. J. Infect. Dis. 36:400.
183. Krzewinski JW, Nguyen CD, Foster JM, Burns JL. 2001. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J. Clin. Microbiol. 39:3597-3602.
184. Kulakov LA, McAlister MB, Ogden KL, Larkin MJ, O'Hanlon JF. 2002. Analysis of bacteria contaminating ultrapure water in industrial systems. Appl. Environ. Microbiol. 68:1548-1555.
185. Labarca JA, et al. 2000. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin. Infect. Dis. 30:195-197.
186. Lafferty KD. 2009. The ecology of climate change and infectious diseases. Ecology 90:888-900.
187. Lai C-H, et al. 2004. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J. Microbiol. Immunol. Infect. 37:350-358.
188. Lai C-H, et al. 2006. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin. Microbiol. Infect. 12:986-991.
189. Laing FPY, et al. 1995. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J. Clin. Microbiol. 33:513-518.
190. Lambert T, Ploy MC, Denis F, Courvalin P. 1999. Characterization of the chromosomal aac(6=)-Iz gene of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 43:2366-2371.
191. Landrum ML, Conger NG, Forgione MA. 2005. Trimethoprimsulfamethoxazole in the treatment of Stenotrophomonas maltophilia osteomyelitis. Clin. Infect. Dis. 40:1551-1552.
192. Lanini S, et al. 2011. Molecular epidemiology of a Pseudomonas aeruginosa hospital outbreak driven by a contaminated disinfectant-soap dispenser. PLoS One 6:e17064. doi:10.1371/journal.pone.0017064.
193. Ledder RG, Gilbert P, Willis C, McBain AJ. 2006. Effects of chronic triclosan exposure upon the antimicrobial susceptibility of 40 ex-situ environmental and human isolates. J. Appl. Microbiol. 100:1132-1140.
194. Lee PA, Tullman-Ercek D, Georgiou G. 2006. The bacterial twinarginine translocation pathway. Annu. Rev. Microbiol. 60:373-395.
195. Li X-Z, Zhang L, McKay GA, Poole K. 2003. Role of the acetyltransferase AAC(6=)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 51:803-811.
196. Li X-Z, Zhang L, Poole K. 2002. SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 46:333-343.
197. Liaqat I, Sabri AN. 2008. Effect of biocides on biofilm bacteria from dental unit water lines. Curr. Microbiol. 56:619-624.
198. Liaw S-J, Lee Y-L, Hsueh P-R. 2010. Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and biofilm formation. Int. J. Antimicrob. Agents 35:126-130.
199. Liaw S-J, Teng L-J, Hsueh P-R, Ho S-W, Luh K-T. 2002. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J. Formos. Med. Assoc. 101:495-501.
200. Lidsky K, Hoyen C, Salvator A, Rice LB, Toltzis P. 2002. Antibioticresistant Gram-negative organisms in pediatric chronic-care facilities. Clin. Infect. Dis. 34:760-766.
201. Lin C-W, Huang Y-W, Hu R-M, Chiang K-H, Yang T-C. 2009. The role of AmpR in regulation of L1 and L2 β-lactamases in Stenotrophomonas maltophilia. Res. Microbiol. 160:152-158.
202. Lin HC, Ma DH, Chen YF, Yeh LK, Hsiao CH. 2011. Late-onset intrascleral dissemination of Stenotrophomonas maltophilia scleritis after pterygium excision. Cornea 30:712-715.
203. LiPuma JJ. 2000. Expanding microbiology of pulmonary infection in cystic fibrosis. Pediatr. Infect. Dis. J. 19:473-474.
204. LiPuma JJ. 2003. Burkholderia and emerging pathogens in cystic fibrosis. Semin. Respir. Crit. Care Med. 24:681-692.
205. LiPuma JJ, Currie BJ, Lum GD, Vandamme PAR. 2007. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas, Delftia, and Acidovorax, p 749-769. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, and Pfaller MA (ed), Manual of clinical microbiology, 9th ed, vol 1. ASM Press, Washington, DC.
206. LiPuma JJ, et al. 2009. In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob. Agents Chemother. 53:249-255.
207. Lockhart SR, et al. 2007. Antimicrobial resistance among Gramnegative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol. 45:3352-3359.
208. Reference deleted.
209. MacDonell MT, Hood MA. 1982. Isolation and characterization of ultramicrobacteria from a gulf coast estuary. Appl. Environ. Microbiol. 43:566-571.
210. Maes M. 1993. Fast classification of plant-associated bacteria in the Xanthomonas genus. FEMS Microbiol. Lett. 113:161-165.
211. Maisetta G, et al. 2009. In vitro bactericidal activity of the N-terminal fragment of the frog peptide esculentin-1b (Esc 1-18) in combination with conventional antibiotics against Stenotrophomonas maltophilia. Peptides 30:1622-1626.
212. Makin SA, Beveridge TJ. 1996. The influence of A-band and B-band lipopolysaccharide on the surface characteristics and adhesion of Pseudomonas aeruginosa to surfaces. Microbiology 142:299-307.
213. Mancini DAP, Mendonça RMZ, Dias ALF, Mendonça RZ, Pinto JR. 2005. Co-infection between influenza virus and flagellated bacteria. Rev. Inst. Med. Trop. Sao Paulo 47:275-280.
214. Mangoni ML, Fiocco D, Mignogna G, Barra D, Simmaco M. 2003. Functional characterization of the 1-18 fragment of esculentin-1b, an antimicrobial peptide from Rana esculenta. Peptides 24:1771-1777.
215. Mangoni ML, et al. 2008. Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrug-resistant nosocomial bacterial strains. Antimicrob. Agents Chemother. 52:85-91.
216. Mann GLB, Campbell TL, Crawford JJ. 1996. Backflow in low-volume suction lines: the impact of pressure changes. J. Am. Dent. Assoc. 127: 611-615.
217. Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A. 2004. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur. Respir. J. 23:98-102.
218. Martínez JL. 2008. Antibiotics and antibiotic resistance genes in natural environments. Science 321:365-367.
219. Martinez RF, Kopp DR, Mangat RK, Snouffer AA, Brooke JS. 2010. Effect of ferric chloride on biofilm formation of Stenotrophomonas maltophilia, abstr II24. Abstr. 60th Annu. Conf. Can. Soc. Microbiol. Canadian Society of Microbiologists, Hamilton, Ontario, Canada.
220. Martínez-Martínez L, Pascual A, Perea EJ. 1990. Effect of three plastic catheters on survival and growth of Pseudomonas aeruginosa. J. Hosp. Infect. 16:311-318.
221. Mary P, Buchet G, Defives C, Hornez JP. 2001. Growth and survival of clinical vs. environmental species of Aeromonas in tap water. Int. J. Food Microbiol. 69:191-198.
222. Marzuillo C, et al. 2009. Molecular characterization of Stenotrophomonas maltophilia isolates from cystic fibrosis patients and the hospital environment. Infect. Control Hosp. Epidemiol. 30:753-758.
223. Masgala A, Galani I, Souli M, Giamarellou H. 2010. Discrepancies between various methods in susceptibility testing and epidemiological analysis of Stenotrophomonas maltophilia clinical isolates. Cent. Eur. J. Public Health 18:119-123.
224. Mauger TF, Kuennen RA, Smith RH, Sawyer W. 2010. Acanthamoeba and Stenotrophomonas maltophilia keratitis with fungal keratitis in the contralateral eye. Clin. Ophthalmol. 4:1207-1209.
225. McKay GA, Woods DE, MacDonald KL, Poole K. 2003. Role of phosphoglucomutase of Stenotrophomonas maltophilia in lipopolysaccharide biosynthesis, virulence, and antibiotic resistance. Infect. Immun. 71: 3068-3075.
226. Reference deleted.
227. Mercuri PS, et al. 2002. Clonal diversity and metallo-β-lactamase production in clinical isolates of Stenotrophomonas maltophilia. Microb. Drug Resist. 8:193-200.
228. Metan G, Hayran M, Hascelik G, Uzun O. 2006. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scand. J. Infect. Dis. 38:527-531.
229. Mett H, Rosta S, Schacher B, Frei R. 1988. Outer membrane permeability and β-lactamase content in Pseudomonas maltophilia clinical isolates and laboratory mutants. Rev. Infect. Dis. 10:765-769.
230. Meyer E, et al. 2006. Stenotrophomonas maltophilia and antibiotic use in German intensive care units: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units). J. Hosp. Infect. 64:238-243.
231. Micozzi A, et al. 2000. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin. Infect. Dis. 31:705-711.
232. Millar FA, Simmonds NJ, Hodson ME. 2009. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J. Cyst. Fibros. 8:386-391.
233. Minkwitz A, Berg G. 2001. Comparison of antifungal activities and 16S ribosomal DNA sequences of clinical and environmental isolates of Stenotrophomonas maltophilia. J. Clin. Microbiol. 39:139-145.
234. Mooney L, Kerr KG, Denton M. 2001. Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients. Int. J. Antimicrob. Agents 17:63-66.
235. Moore JE, Xu J, Millar BC, Courtney J, Elborn JS. 2003. Development of a Gram-negative selective agar (GNSA) for the detection of Gramnegative microflora in sputa in patients with cystic fibrosis. J. Appl. Microbiol. 95:160-166.
236. Muder RR, et al. 1996. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin. Infect. Dis. 22:508-512.
237. Müller-Premru M, et al. 2008. Cluster of Stenotrophomonas maltophilia endocarditis after prosthetic valve replacement. Wien. Klin. Wochenschr. 120:566-570.
238. Nakamura A, et al. 2010. Diagnostic value of PCR analysis of bacteria and fungi from blood in empiric-therapy-resistant febrile neutropenia. J. Clin. Microbiol. 48:2030-2036.
239. Nakatsu CH, Fulthorpe RR, Holland BA, Peel MC, Wyndham RC. 1995. The phylogenetic distribution of a transposable dioxygenase from the Niagara River watershed. Mol. Ecol. 4:593-603.
240. Neal DJ, Wilkinson SG. 1982. Lipopolysaccharides from Pseudomonas maltophilia. Structural studies of the side-chain, core, and lipid-A regions of the lipopolysaccharide from strain NCTC 10257. Eur. J. Biochem. 128:143-149.
241. Nelson DR, Sadlowski Y, Eguchi M, Kjelleberg S. 1997. The starvationstress response of Vibrio (Listonella) anguillarum. Microbiology 143: 2305-2312.
242. Nesme X, Vaneechoutte M, Orso S, Hoste B, Swings J. 1995. Diversity and genetic relatedness with genera Xanthomonas and Stenotrophomonas using restriction endonuclease site differences of PCR-amplified 16S rRNA gene. Syst. Appl. Microbiol. 18:127-135.
243. Nguyen MH, Muder RR. 1994. Meningitis due to Xanthomonas maltophilia: case report and review. Clin. Infect. Dis. 19:325-326.
244. Nicodemo AC, Araujo MRE, Ruiz AS, Gales AC. 2004. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J. Antimicrob. Chemother. 53: 604-608.
245. Nicodemo AC, Garcia Paez JI. 2007. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur. J. Clin. Microbiol. Infect. Dis. 26:229-237.
246. Nicoletti M, et al. 2011. Stenotrophomonas maltophilia strains from cystic fibrosis patients: genomic variability and molecular characterization of some virulence determinants. Int. J. Med. Microbiol. 301:34-43.
247. Nseir S, et al. 2006. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit. Care Med. 34:2959-2966.
248. O'Brien DP, Currie BJ, Krause VL. 2000. Nontuberculous mycobacterial disease in northern Australia: a case series and review of the literature. Clin. Infect. Dis. 31:958-968.
249. O'Donnell MJ, Shore AC, Coleman DC. 2006. A novel automated waterline cleaning system that facilitates effective and consistent control of microbial biofilm contamination of dental chair unit waterlines: a one-year study. J. Dent. 34:648-661.
250. O'Donnell MJ, Tuttlebee CM, Falkiner FR, Coleman DC. 2005. Bacterial contamination of dental chair units in a modern dental hospital caused by leakage from suction system hoses containing extensive biofilm. J. Hosp. Infect. 59:348-360.
251. Okazaki A, Avison MB. 2008. Induction of L1 and L2 β-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpRtype regulator. Antimicrob. Agents Chemother. 52:1525-1528.
252. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.
253. Omenn GS. 2010. Evolution and public health. Proc. Natl. Acad. Sci. U. S. A. 107:1702-1709.
254. Ortolano GA, et al. 2005. Hospital water point-of-use filtration: a complementary strategy to reduce the risk of nosocomial infection. Am. J. Infect. Control 33:S1-S19.
255. Page MG, et al. 2011. In vitro and in vivo properties of BAL30376, a β-lactam and dual β-lactamase inhibitor combination with enhanced activity against Gram-negative bacilli that express multipleβ-lactamases. Antimicrob. Agents Chemother. 55:1510-1519.
256. Pages D, et al. 2008. Heavy metal tolerance in Stenotrophomonas maltophilia. PLoS One 3:e1539. doi:10.1371/journal.pone.0001539.
257. Pakyz AL, Farr BM. 2009. Rates of Stenotrophomonas maltophilia colonization and infection in relation to antibiotic cycling protocols. Epidemiol. Infect. 137:1679-1683.
258. Palleroni NJ. 2005. Genus IX. Stenotrophomonas Palleroni and Bradbury 1993, 608, p 107-115. In Brenner DJ, Krieg NR, Staley JT, Garrity GM (ed), Bergey's manual of systematic bacteriology, vol 2. Springer Science+Business Media Inc., New York, NY.
259. Palleroni NJ, Bradbury JF. 1993. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983. Int. J. Syst. Bacteriol. 43:606-609.
260. Palleroni NJ, Kunisawa R, Contopoulou R, Doudoroff M. 1973. Nucleic acid homologies in the genus Pseudomonas. Int. J. Syst. Bacteriol. 23:333-339.
261. Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. 1995. Stenotrophomonas maltophilia: an unusual case of biliary sepsis. Clin. Infect. Dis. 21:1032-1034.
262. Penland RL, Wilhelmus KR. 1996. Stenotrophomonas maltophilia ocular infections. Arch. Ophthalmol. 114:433-436.
263. Perola O, et al. 2002. Recurrent Sphingomonas paucimobilis-bacteraemia associated with a multi-bacterial water-borne epidemic among neutropenic patients. J. Hosp. Infect. 50:196-201.
264. Petersen BT, et al. 2011. Multisociety guideline on reprocessing flexible GI endoscopes: 2011. Infect. Control Hosp. Epidemiol. 32:527-537.
265. Petridou E, Filioussis G, Karavanis E, Kritas SK. 2010. Stenotrophomonas maltophilia as a causal agent of pyogranulomatous hepatitis in a buffalo (Bubalus bubalis). J. Vet. Diagn. Invest. 22:772-774.
266. Pizarro F, Olivares M, Araya M, Gidi V, Uauy R. 2001. Gastrointestinal effects associated with soluble and insoluble copper in drinking water. Environ. Health Perspect. 109:949-952.
267. Pompilio A, et al. 2010. Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomona maltophilia from cystic fibrosis. J. Med. Microbiol. 59:76-81.
268. Pompilio A, et al. 2010. Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol. 10:102. doi:10.1186/1471-2180-10-102.
269. Poole K. 2004. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10:12-26.
270. Potera C. 1999. Forging a link between biofilms and disease. Science 283:1837-1838.
271. Pradel N, Delmas J, Wu LF, Santini CL, Bonnet R. 2009. Sec-and Tat-dependent translocation of β-lactamases across the Escherichia coli inner membrane. Antimicrob. Agents Chemother. 53:242-248.
272. Public Health Laboratory Service. 1993. Ice as a source of infection acquired in hospital. CDR Wkly. 3:53.
273. Qureshi A, Mooney L, Denton M, Kerr KG. 2005. Stenotrophomonas maltophilia in salad. Emerg. Infect. Dis. 11:1157-1158.
274. Raad I, et al. 2008. Anti-adherence activity and antimicrobial durability of anti-infective-coated catheters against multidrug-resistant bacteria. J. Antimicrob. Chemother. 62:746-750.
275. Rahmati-Bahram A, Magee JT, Jackson SK. 1997. Effect of temperature on aminoglycoside binding sites in Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 39:19-24.
276. Ramsey BW, et al. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Firbosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340:23-30.
277. Ranasinha C, et al. 1993. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 342:199-202.
278. Razvi S, et al. 2009. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005. Chest 136:1554-1560.
279. Rivas R, García-Fraile P, Mateos PF, Martinez-Molina E, Velázquez E. 2009. Phylogenetic diversity of fast-growing bacteria isolated from superficial water of Lake Martel, a saline subterranean lake in Mallorca Island (Spain) formed by filtration from the Mediterranean Sea through underground rocks. Adv. Stud. Biol. 1:333-344.
280. Robinson M, et al. 1997. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 52: 900-903.
281. Rocco F, De Gregorio E, Colonna B, Di Nocera PP. 2009. Stenotrophomonas genomes: a start-up comparison. Int. J. Med. Microbiol. 299: 535-546.
282. Rocco F, De Gregorio E, Di Nocera PP. 2010. A giant family of short palindromic sequences in Stenotrophomonas maltophilia. FEMS Microbiol. Lett. 308:185-192.
283. Rogues AM, et al. 2001. Electronic ventilator temperature sensors as a potential source of respiratory tract colonization with Stenotrophomonas maltophilia. J. Hosp. Infect. 49:289-292.
284. Rojas P, Garcia E, Calderón GM, Ferreira F, Rosso M. 2009. Successful treatment of Stenotrophomonas maltophilia meningitis in a preterm baby boy: a case report. J. Med. Case Rep. 3:7389. doi:10.4076/1752-1947-3-7389.
285. Rolston KVI. 2009. New antimicrobial agents for the treatment of bacterial infections in cancer patients. Hematol. Oncol. 27:107-114.
286. Romanenko LA, et al. 2008. Occurrence and antagonistic potential of Stenotrophomonas strains isolated from deep-sea invertebrates. Arch. Microbiol. 189:337-344.
287. Roscetto E, et al. 2008. PCR-based rapid genotyping of Stenotrophomonas maltophilia isolates. BMC Microbiol. 8:202. doi:10.1186/1471-2180-8-202.
288. Ross RA, Marzec G. 1984. The bacterial diseases of reptiles. Their epidemiology, control, diagnosis and treatment, p 3, 7-10, 14-18. Institute for Herpetological Research, Stanford University School of Medicine, Stanford, CA.
289. Rusin P, Orosz-Coughlin P, Gerba C. 1998. Reduction of faecal coliform, coliform and heterotrophic plate count bacteria in the household kitchen and bathroom by disinfection with hypochlorite cleaners. J. Appl. Microbiol. 85:819-828.
290. Ryan MP, Adley CC. 2010. Sphingomonas paucimobilis: a persistent Gram-negative nosocomial infectious organism. J. Hosp. Infect. 75: 153-157.
291. Ryan RP, et al. 2008. Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa. Mol. Microbiol. 68: 75-86.
292. Sacchetti R, De Luca G, Zanetti F. 2009. Control of Pseudomonas aeruginosa and Stenotrophomonas maltophilia contamination of microfiltered water dispensers with peracetic acid and hydrogen peroxide. Int. J. Food Microbiol. 132:162-166.
293. Safdar A, Rolston KV. 2007. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin. Infect. Dis. 45:1602-1609.
294. Saiman L, Chen Y, San Gabriel P, Knirsch C. 2002. Synergisitic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46:1105-1107.
295. Saino Y, Inoue M, Mitsuhashi S. 1984. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob. Agents Chemother. 25:362-365.
296. Saino Y, Kobayashi F, Inoue M, Mitsuhashi S. 1982. Purification and properties of inducible penicillin β-lactamase isolated from Pseudomonas maltophilia. Antimicrob. Agents Chemother. 22:564-570.
297. Sakhnini E, Weissmann A, Oren I. 2002. Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water. Am. J. Med. Sci. 323:269-272.
298. Sánchez MB, Hernández A, Martínez JL. 2009. Stenotrophomonas maltophilia drug resistance. Future Microbiol. 4:655-660.
299. Sánchez MB, Hernández A, Rodríguez-Martínez JM, Martínez-Martínez L, Martínez JL. 2008. Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants. BMC Microbiol. 8:148. doi:10.1186/1471-2180-8-148.
300. Sánchez MB, Martínez JL. 2010. SmQnr contributes to the intrinsic resistance to quinolones of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 54:580-581.
301. Sánchez P, Alonso A, Martínez JL. 2002. Cloning and characterization of SmeT, a repressor of the Stenotrophomonas maltophilia multidrug efflux pump SmeDEF. Antimicrob. Agents Chemother. 46:3386-3393.
302. Sánchez P, Alonso A, Martínez JL. 2004. Regulatory regions of smeDEF in Stenotrophomonas maltophilia strains expressing different amounts of the multidrug efflux pump SmeDEF. Antimicrob. Agents Chemother. 48:2274-2276.
303. Sanchez P, Moreno E, Martinez JL. 2005. The biocide triclosan selects Stenotrophomonas maltophilia mutants that overproduce the SmeDEF multidrug efflux pump. Antimicrob. Agents Chemother. 49:781-782.
304. San Gabriel P, et al. 2004. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:168-171.
305. Sanschagrin F, Levesque RC. 2005. A specific peptide inhibitor of the class B metallo-β-lactamase L-1 from Stenotrophomonas maltophilia identified using phage display. J. Antimicrob. Chemother. 55:252-255.
306. Savini V, et al. 2010. Chloramphenicol and rifampin may be the only options against Stenotrophomonas maltophilia. A tale of a colonized bladder device in a patient with myelofibrosis. Infez. Med. 18:193-197.
307. Schable B, Villarino ME, Favero MS, Miller JM. 1991. Application of multilocus enzyme electrophoresis to epidemiologic investigations of Xanthomonas maltophilia. Infect. Control Hosp. Epidemiol. 12:163-167.
308. Schaumann R, Laurin F, Rodloff AC. 2008. Molecular typing of clinical isolates of Stenotrophomonas maltophilia by pulsed-field gel electrophoresis and random primer PCR fingerprinting. Int. J. Hyg. Environ. Health 211:292-298.
309. Schreckenberger PC, Daneshvar MI, Hollis DG. 2007. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative Gram-negative rods, p 770-802. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA(ed), Manual of clinical microbiology, 9th ed, vol 1. ASM Press, Washington, DC.
310. Sefcick A, Tait RC, Wood B. 1999. Stenotrophomonas maltophilia: an increasing problem in patients with acute leukaemia. Leuk. Lymphoma 35:207-211.
311. Sheffer PJ, Stout JE, Wagener MM, Muder RR. 2005. Efficacy of new point-of-use water filter for preventing exposure to Legionella and waterborne bacteria. Am. J. Infect. Control 33:S20-S25.
312. Shih H-Y, Lin YE. 2010. Efficacy of copper-silver ionization in controlling biofilm-and plankton-associated waterborne pathogens. Appl. Environ. Microbiol. 76:2032-2035.
313. Shimizu K, et al. 2008. Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 52:3823-3825.
314. Shintani M, Fukushima N, Tezuka M, Yamane H, Nojiri H. 2008. Conjugative transfer of the IncP-7 carbazole degradative plasmid, pCAR1, in river water samples. Biotechnol. Lett. 30:117-122.
315. Shuman EK. 2010. Global climate change and infectious diseases. N. Engl. J. Med. 362:1061-1063.
316. Silbaq FS. 2009. Viable ultramicrocells in drinking water. J. Appl. Microbiol. 106:106-117.
317. Silvestry-Rodriguez N, Bright KR, Slack DC, Uhlmann DR, Gerba CP. 2008. Silver as a residual disinfectant to prevent biofilm formation in water distribution systems. Appl. Environ. Microbiol. 74:1639-1641.
318. Simões LC, Simões M, Oliveira R, Vieira MJ. 2007. Potential of the adhesion of bacteria isolated from drinking water to materials. J. Basic Microbiol. 47:174-183.
319. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. 2002. A component of innate immunity prevents bacterial biofilm development. Nature 417: 552-555.
320. Steinkamp G, et al. 2005. Prospective evaluation of emerging bacteria in cystic fibrosis. J. Cyst. Fibros. 4:41-48.
321. Stokes HW, Tomaras C, Parsons Y, Hall RM. 1993. The partial 3=-conserved segment duplications in the integrons In6 from pSa and In7 from pDGO100 have a common origin. Plasmid 30:39-50.
322. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. 2009. Plasmidmediated quinolone resistance: a multifaceted threat. Clin. Microbiol. Rev. 22:664-689.
323. Sun H-Y, et al. 2010. Infections occurring during extracorporeal membrane oxygenation use in adult patients. J. Thorac. Cardiovasc. Surg. 140:1125-1132.
324. Sundaram S, Auriemma M, Howard G, Jr, Brandwein H, Leo F. 1999. Application of membrane filtration for removal of diminutive bioburden organisms in pharmaceutical products and processes. PDA J. Pharm. Sci. Technol. 53:186-201.
325. Swings J, De Vos P, Van den Mooter M, De Ley J. 1983. Transfer of Pseudomonas maltophilia Hugh 1981 to the genus Xanthomonas as Xanthomonas maltophilia (Hugh 1981) comb. nov. Int. J. Syst. Bacteriol. 33:409-413.
326. Takigawa M, et al. 2008. Extremely late pacemaker-infective endocarditis due to Stenotrophomonas maltophilia. Cardiology 110:226-229.
327. Teng S-O, et al. 2009. Bacterial contamination of patients' medical charts in a surgical ward and the intensive care unit: impact on nosocomial infections. J. Microbiol. Immunol. Infect. 42:86-91.
328. Toleman MA, Bennett PM, Bennett DMC, Jones RN, Walsh TR. 2007. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg. Infect. Dis. 13:559-565.
329. Toleman MA, Bennett PM, Walsh TR. 2006. Common regions e.g. orf513 and antibiotic resistance: IS91-like elements evolving complex class I integrons. J. Antimicrob. Chemother. 58:1-6.
330. Toleman MA, Bennett PM, Walsh TR. 2006. ISCR elements: novel gene-capturing systems of the 21st century? Microbiol. Mol. Biol. Rev. 70:296-316.
331. Traub WH, Leonhard B, Bauer D. 1998. Stenotrophomonas (Xanthomonas) maltophilia: in vitro susceptibility to selected antimicrobial drugs, single and combined, with or without defibrinated human blood. Chemotherapy 44:293-304.
332. Trautmann M, Halder S, Hoegel J, Royer H, Haller M. 2008. Pointof-use water filtration reduces endemic Pseudomonas aeruginosa infections on a surgical intensive care unit. Am. J. Infect. Control 36:421-429.
333. Tseng C-C, et al. 2009. Risk factors for mortality in patients with nosocomial Stenotrophomonas maltophilia pneumonia. Infect. Control Hosp. Epidemiol. 30:1193-1202.
334. Tungekar R, Zuniga M, Brooke JS. 2006. Investigation of a Stenotrophomonas maltophilia mutant that produces more biofilm than its parental isolate, abstr B-071. Abstr. 106th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.
335. Turrientes MC, et al. 2010. Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations. Appl. Environ. Microbiol. 76:1746-1758.
336. Uma B, Prabhakar K, Rajendran S, Kavitha K, Sarayu YL. 2009. Antibiotic sensitivity and plasmid profiles of Escherichia coli isolated from pediatric diarrhea. J. Global Infect. Dis. 1:107-110.
337. Valdezate S, Vindel A, Loza E, Baquero F, Cantón R. 2001. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob. Agents Chemother. 45:1581-1584.
338. Valdezate S, et al. 2001. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg. Infect. Dis. 7:113-122.
339. Valdezate S, Vindel A, Saéz-Nieto JA, Baquero F, Cantón R. 2005. Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains. J. Antimicrob. Chemother. 56: 220-223.
340. Valenza G, et al. 2008. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J. Cyst. Fibros. 7:123-127.
341. Van den Mooter M, Swings J. 1990. Numerical analysis of 295 phenotypic features of 266 Xanthomonas strains and related strains and an improved taxonomy of the genus. Int. J. Syst. Bacteriol. 40:348-369.
342. Vartivarian SE, Papadakis KA, Anaissie EJ. 1996. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch. Intern. Med. 156:433-435.
343. Vartivarian SE, Papadakis KA, Palacios JA, Manning JT, Jr, Anaissie EJ. 1994. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. Ann. Intern. Med. 121:969-973.
344. Vento S, Cainelli F, Temesgen Z. 2008. Lung infections after cancer chemotherapy. Lancet Oncol. 9:982-992.
345. Verweij PE, et al. 1998. Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water. Epidemiol. Infect. 120:251-256.
346. Victor MA, Arpi M, Bruun B, Jønsson V, Hansen MM. 1994. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand. J. Infect. Dis. 26:163-170.
347. Vieira CD, et al. 2011. Count, identification and antimicrobial susceptibility of bacteria recovered from dental solid waste in Brazil. Waste Manag. 31:1327-1332. doi:10.1016/j.wasman.2010.12.016.
348. Vo A, Davis N, Watts P, Brooke JS. 2005. Characterization of a Stenotrophomonas maltophilia mutant that produces excessive biofilm on abiotic surfaces, abstr B-1273. In Abstr. Joint Meet. 3 Div. Int. Union Microbiol. Soc. American Society for Microbiology, Washington, DC.
349. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. 2008. In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J. Antimicrob. Chemother. 61:371-374.
350. Waharte F, Steenkeste K, Briandet R, Fontaine-Aupart M-P. 2010. Diffusion measurements inside biofilms by image-based fluorescence recovery after photobleaching (FRAP) analysis with a commercial confocal laser scanning microscope. Appl. Environ. Microbiol. 76:5860-5869.
351. Wainwright CE, et al. 2009. Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax 64:926-931.
352. Walsh TR, et al. 1994. Sequence analysis of the L1 metallo-β-lactamase from Xanthomonas maltophilia. Biochim. Biophys. Acta 1218:199-201.
353. Walsh TR, MacGowan AP, Bennett PM. 1997. Sequence analysis and enzyme kinetics of the L2 serine β-lactamase from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41:1460-1464.
354. Wang C, Zhan Q, Mi Z, Huang Z, Chen G. 2008. Distribution of the antiseptic-resistance gene qacEΔ1 in 283 clinical isolates of Gramnegative bacteria in China. J. Hosp. Infect. 69:394-396.
355. Wang J-L, Chen M-L, Lin YE, Chang S-C, Chen Y-C. 2009. Association between contaminated faucets and colonization or infection by nonfermenting Gram-negative bacteria in intensive care units in Taiwan. J. Clin. Microbiol. 47:3226-3230.
356. Wang SA, et al. 1999. An outbreak of gram-negative bacteremia in hemodialysis patients traced to hemodialysis machine waste drain ports. Infect. Control Hosp. Epidemiol. 20:746-751.
357. Wang W-S, Liu C-P, Lee C-M, Huang F-Y. 2004. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J. Microbiol. Immunol. Infect. 37:359-365.
358. Wareham DW, Gordon NC, Shimizu K. 2011. Two new variants of and creation of a repository for Stenotrophomonas maltophilia quinolone protection protein (Smqnr) genes. Int. J. Antimicrob. Agents 37:89-90.
359. Waters V, et al. 2011. Stenotrophomonas maltophilia in cystic fibrosis. Serologic response and effect on lung disease. Am. J. Respir. Crit. Care Med. 183:635-640.
360. Waters VJ, et al. 2007. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect. Immun. 75:1698-1703.
361. Watson CM, Whitehouse RLS. 1993. Possibility of cross-contamination between dental patients by means of the saliva ejector. J. Am. Dent. Assoc. 124:77-80.
362. Watzke H, et al. 1989. Bacterial contamination of dialysate in dialysisassociated endotoxaemia. J. Hosp. Infect. 13:109-115.
363. Weber DJ, Rutala WA, Blanchet CN, Jordan M, Gergen MF. 1999. Faucet aerators: a source of patient colonization with Stenotrophomonas maltophilia. Am. J. Infect. Control 27:59-63.
364. Whitby PW, et al. 2000. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J. Clin. Microbiol. 38: 4305-4309.
365. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. 2002. Extracellular DNA required for bacterial biofilm formation. Science 295:1487.
366. White AS, Godard RD, Belling C, Kasza V, Beach RL. 2010. Beverages obtained from soda fountain machines in the U.S. contain microorganisms, including coliform bacteria. Int. J. Food Microbiol. 137:61-66.
367. Wilkinson FH, Kerr KG. 1998. Bottled water as a source of multiresistant Stenotrophomonas and Pseudomonas species for neutropenic patients. Eur. J. Cancer Care 7:12-14.
368. Windhorst S, et al. 2002. The major extracellular protease of the nosocomial pathogen Stenotrophomonas maltophilia: characterization of the protein and molecular cloning of the gene. J. Biol. Chem. 277: 11042-11049.
369. Wishart MM, Riley TV. 1976. Infection with Pseudomonas maltophilia: hospital outbreak due to contaminated disinfectant. Med. J. Aust. 2:710-712.
370. Wladis EJ. 20 December 2010, posting date. Dacryocystitis secondary to Stenotrophomonas maltophilia infection. Ophthal. Plast. Reconstr. Surg. [Epub ahead of print.] doi:10.1097/IOP.obo13e318201ca3b.
371. Wood GC, Underwood EL, Croce MA, Swanson JM, Fabian TC. 2010. Treatment of recurrent Stenotrophomonas maltophilia ventilatorassociated pneumonia with doxycycline and aerosolized colistin. Ann. Pharmacother. 44:1665-1668.
372. Wu P-S, et al. 2006. Stenotrophomonas maltophilia bacteremia in pediatric patients-a 10 year analysis. J. Microbiol. Immunol. Infect. 39: 144-149.
373. Yang L, et al. 2007. Effects of iron on DNA release and biofilm development by Pseudomonas aeruginosa. Microbiology 153:1318-1328.
374. Yang T-C, Huang Y-W, Hu R-M, Huang S-C, Lin Y-T. 2009. AmpDI is involved in expression of the chromosomal L1 and L2 β-lactamases of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 53: 2902-2907.
375. Yemisen M, Mete B, Tunali Y, Yentur E, Ozturk R. 2008. A meningitis case due to Stenotrophomonas maltophilia and review of the literature. Int. J. Infect. Dis. 12:e125-e127. doi:10.1016/j.ijid.03.028.
376. Yeshurun M, et al. 2010. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection 38:211-215.
377. Yorioka K, Oie S, Kamiya A. 2010. Microbial contamination of suction tubes attached to suction instruments and preventive methods. Jpn. J. Infect. Dis. 63:124-127.
378. Yu VL, Felegie TP, Yee RB, Pasculle AW, Taylor FH. 1980. Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. J. Infect. Dis. 142:602-607.
379. Zelenitsky SA, Iacovides H, Ariano RE, Harding GKM. 2005. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 51:39-43.
380. Zgair AK, Chhibber S. 2010. Immunological and pathological aspects of respiratory tract infection with Stenotrophomonas maltophilia in BALB/c mice. J. Microbiol. Biotechnol. 20:1585-1591.
381. Zgair AK, Chhibber S. 2011. Adhesion of Stenotrophomonas maltophilia to mouse tracheal mucus is mediated through flagella. J. Med. Microbiol. 60:1032-1037.
382. Zhang J, Kong F. 2002. Synthesis of a xylosylated rhamnose pentasaccharide: the repeating unit of the O-specific side chain of lipopolysaccharides from the reference strains for Stenotrophomonas maltophilia serogroup O18. J. Carbohydr. Chem. 21:89-97.
383. Zhang L, Li X-Z, Poole K. 2000. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob. Agents Chemother. 44:287-293.